Reducing dysphagia with palliative 2D high-dose-rate brachytherapy improves survival in esophageal cancer
Year: 2019
Type: article
Abstract: Purpose: The goal of this study was to assess the effectiveness of dysphagia relief and overall survival in patients with advanced esophageal cancer treated with palliative high-dose-rate (HDR) brachytherapy (BT) without computed tomography-based planning.Material and methods: Palliative 2D HDR-BT was used to treat 93 patients with advanced or incurable esophageal cancer in a regional cancer center from October 2010 to December 2016.Before the treatment patients presented the following grades of dysphagia: 0 -0%, I -57%, II -33.3%, III -6.5%, IV -3.2%.The planned dose was 22.5 Gy in 3 fractions.The median age of patients was 65 years (45-88).Squamous cell carcinoma was diagnosed in 59.4%, adenocarcinoma in 22.6%, and other histological types of tumors in 6.7% of cases.The histopathological report was unknown in 11.3% of patients.Results: The mean follow-up was 5.0 months (range 1-43).The median tumor length was 72.5 mm.Due to BT dysphagia was significantly decreased: grade 0 -38.7%,I -31.2%,II -20.4%, IV -1.1% (p < 0.001).Dysphagia relief was achieved in 55% of patients and lasted for a mean time of 4.6 months; stabilization occurred in 31% and deterioration in 14%.The patients with partial or complete dysphagia relief lived longer (5.8 vs. 4.1 months, p = 0.02).The patients with a length of the tumor less than 72.5 mm, histopathologically confirmed adenocarcinoma or after dilatation with a metal stent subsequently to BT had improved overall survival as well (7.1 vs. 3.6; 8.0 vs. 4.1; 6.5 vs. 4.0 months, respectively; p < 0.05).The primary localization and primary grade of dysphagia were not factors that influenced the survival of patients.The logistic regression model did not reveal any predictors for treatment response.Conclusions: 2D HDR-BT reduces dysphagia and prolongs survival in patients who respond to the treatment.It meets the assumption of palliative treatment for advanced esophageal cancer because of its simplicity and effectiveness.
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $269
OpenAlex ID: W2996882016
